Looking Ahead: The Evolving Oncology Landscape

 

Looking Ahead: The Evolving Oncology Landscape

  • This page as PDF

Summary

Avalere experts examined the changing oncology landscape amid the COVID-19 pandemic.
Please note: This is an archived post. Some of the information and data discussed in this article may be out of date. It is preserved here for historical reference but should not be used as the basis for business decisions. Please see our main Insights section for more recent posts.

The oncology landscape continues to evolve, with delays to preventative screenings and care during the COVID-19 pandemic and an influx of approved immunotherapy and other targeted therapy products. Stakeholders will be impacted by a changing payer mix with growth in managed markets, continued investment in diagnosis and treatment options, and a focus on value. Join us for a discussion on these shifts and what to expect going forward.

Key Topics:

  • Impact of COVID-19 on access and health equity, including insurance coverage shifts, changes in reimbursement, and telehealth adoption
  • Areas of innovation and market growth, including advances in diagnosis and treatment
  • Strategies to demonstrate value, especially for targeted therapies

Panelists

Moderator
Sarah Butler , Head, Client Solutions, Marketing & Operations

Sarah Butler specializes in evidence-based medicine, value-based contracting, and strategy development.

Speaker
Roy Beveridge , Managing Director, Market Access & Reimbursement

Roy Beveridge, MD, a medical oncologist, provides insights and support across all Avalere practices, including the Center for Healthcare Transformation, Financial Services, and the Market Access team.

Speaker
Omar Hafez , Practice Director, Market Access & Reimbursement

Omar advises a range of clients on issues including supply chain, drug pricing, launch strategy, and oncology market analytics and planning.

Guest Speaker
Allison Petrilla , Managing Director, Health Economics & Advanced Analytics, Inovalon
Allison Petrilla works closely with life sciences clients to design observational research studies, health economic evaluations, and market landscape assessments.

Related Content

Sign up to receive more insights about RWE and Patient-Centered Outcomes
Please enter your email address to be notified when new RWE and Patient-Centered Outcomes insights are published.

Back To Top